data

Luxurynsight and Heuritech, two French AI & Data Leaders unite to unlock next-level data intelligence for Luxury, Fashion and Beauty BrandsLuxurynsight and Heuritech, two French AI & Data Leaders unite to unlock next-level data intelligence for Luxury, Fashion and Beauty Brands

Luxurynsight and Heuritech, two French AI & Data Leaders unite to unlock next-level data intelligence for Luxury, Fashion and Beauty Brands

PARIS, Dec. 2, 2024 /PRNewswire/ -- As from November 2024, Heuritech has officially joined the Luxurynsight Group. This strategic operation marks…

3 months ago
Luxurynsight and Heuritech, two French AI & Data Leaders unite to unlock next-level data intelligence for Luxury, Fashion and Beauty BrandsLuxurynsight and Heuritech, two French AI & Data Leaders unite to unlock next-level data intelligence for Luxury, Fashion and Beauty Brands

Luxurynsight and Heuritech, two French AI & Data Leaders unite to unlock next-level data intelligence for Luxury, Fashion and Beauty Brands

PARIS, Dec. 2, 2024 /PRNewswire/ -- As from November 2024, Heuritech has officially joined the Luxurynsight Group. This strategic operation marks…

3 months ago
Schneider Electric advances environmental impact transparency in MEP by sharing product data through One Click LCASchneider Electric advances environmental impact transparency in MEP by sharing product data through One Click LCA

Schneider Electric advances environmental impact transparency in MEP by sharing product data through One Click LCA

First-of-its-kind environmental initiative addresses the critical data shortage for MEP products needed to decarbonize building services.RUEIL-MALMAISON, France, Nov. 28, 2024 /PRNewswire/…

4 months ago
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC.Updated results of…

4 months ago
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC.Updated results of…

4 months ago
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC.Updated results of…

4 months ago
Atomic Data Becomes Official IT Provider of the Fishers Event CenterAtomic Data Becomes Official IT Provider of the Fishers Event Center

Atomic Data Becomes Official IT Provider of the Fishers Event Center

MINNEAPOLIS, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Atomic Data today announced a multi-year agreement to make it the Official IT…

4 months ago
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 MonthsOpen-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

November 18, 2024 11:15 ET | Source: BridgeBio Pharma, Inc. - Acoramidis demonstrated the earliest known time to separation in…

4 months ago
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

SAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted…

4 months ago